Korro Bio (KRRO) Retained Earnings (2018 - 2026)
Korro Bio's (KRRO) quarterly Retained Earnings came in at $525.8 million in Q2 2026, up 22.09% on a YoY basis from $430.7 million in Q2 2025, and up 0.52% quarter-over-quarter from $523.1 million in Q1 2026.
Analysis
Korro Bio (KRRO) Retained Earnings (2018 - 2026) Analysis & Trends
Korro Bio (KRRO) has reported Retained Earnings for 9 consecutive years, with $525.8 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Retained Earnings rose 22.09% year-over-year to $525.8 million; the trailing twelve-month figure through Jun 2026 stood at $525.8 million (up 22.09% YoY), and the FY2025 full-year result was $435.1 million, up 1.95% from the prior year.
- Retained Earnings grew to $525.8 million in Q2 2026 per KRRO's latest filing, from $523.1 million in the prior quarter.
- Across five years, Retained Earnings topped out at $525.8 million in Q2 2026 and bottomed at -$101.8 million in Q4 2022.
- Historically, Retained Earnings has averaged $368.4 million across 5 years, with a median of $388.2 million in 2024.
- The sharpest annual moves came in 2022 and 2023: Retained Earnings sank 132.75% in 2022, then surged 446.56% in 2023.
- Over 5 years, Retained Earnings stood at -$101.8 million in 2022, then soared by 446.56% to $352.9 million in 2023, then climbed by 20.92% to $426.7 million in 2024, then rose by 1.95% to $435.1 million in 2025, then rose by 20.85% to $525.8 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered $525.8 million, $523.1 million, and $435.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.01 Bn | 193.02 Bn | 7.24 Bn | -22.28 Bn |
| 2 | Gilead Sciences | 179.98 Bn | 176.80 Bn | 6.22 Bn | 9.53 Bn |
| 3 | Vertex Pharmaceuticals | 131.45 Bn | 123.60 Bn | 2.84 Bn | 15.69 Bn |
| 4 | Regeneron Pharmaceuticals | 82.02 Bn | 74.03 Bn | 3.93 Bn | 37.62 Bn |
| 5 | Argenx Se | 60.35 Bn | 55.16 Bn | 1.37 Bn | 558.00 Mn |
| 6 | Moderna | 53.69 Bn | 48.55 Bn | 52.00 Mn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 33.11 Bn | 29.80 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Biogen | 31.93 Bn | 30.64 Bn | 1.96 Bn | 20.97 Bn |
| 9 | Roivant Sciences | 29.21 Bn | 29.21 Bn | 1.16 Mn | 5.13 Bn |
| 10 | Korro Bio | 227.98 Mn | 112.95 Mn | - | 525.79 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 525.79 Mn |
| Mar 31, 2026 | 523.09 Mn |
| Dec 31, 2025 | 435.06 Mn |
| Sep 30, 2025 | 432.61 Mn |
| Jun 30, 2025 | 430.66 Mn |
| Mar 31, 2025 | 428.66 Mn |
| Dec 31, 2024 | 426.72 Mn |
| Sep 30, 2024 | 424.44 Mn |
| Jun 30, 2024 | 422.44 Mn |
| Mar 31, 2024 | 353.91 Mn |
| Dec 31, 2023 | 352.91 Mn |
| Sep 30, 2023 | 340.31 Mn |
| Jun 30, 2023 | 337.38 Mn |
| Mar 31, 2023 | 334.49 Mn |
| Dec 31, 2022 | -101.83 Mn |
| Sep 30, 2022 | 326.62 Mn |
| Jun 30, 2022 | 320.97 Mn |
| Mar 31, 2022 | 316.40 Mn |
| Dec 31, 2021 | 310.94 Mn |
| Sep 30, 2021 | 305.66 Mn |